Canada approves first anti-COVID-19 booster dose for children ages 5-11

Par :| Key words : Canada-COVID-19-vaccination
French.china.org.cn| Updated on 20-08-2022

Canada’s drug regulator announced on Friday that it has authorized the use of Comirnaty, Pfizer-BioNTech’s COVID-19 vaccine, as a booster dose for children aged 5 to 11.

The Health Canada agency has said that this booster dose is an excellent solution to restore protection within this age group, especially for children at high risk of serious illness.

The National Advisory Committee on Immunization (NACI) meanwhile released national guidelines on Friday for the use of this booster dose.

NACI has recommended that children 5 to 11 years of age with an underlying condition that puts them at high risk for severe COVID-19, such as immunocompromised children, be offered an initial booster dose of 10 mcg of Comirnaty at least 6 months following their primary vaccination.

<!–enpproperty 783807272022-08-20 06:32:48:302Canada-COVID-19-vaccin10027176468ActualitéActualitéhttp://french.china.org.cn/foreign/txt/2022-08/20/content_78380727.htmnullAgence de presse XinhuaL’organisme canadien de réglementation des médicaments a annoncé vendredi avoir autorisé l’utilisation du Comirnaty, le vaccin anti-COVID-19 de Pfizer-BioNTech, comme dose de rappel pour les enfants âgés de 5 à 11 ans.1/enpproperty–>

Follow China.org.cn on

Twitter
et Facebook to join the conversation.